nach oben

International Journal of Clinical Oncology

Erschienen in:

01.02.2013 | Original Article

The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer

verfasst von: Xiao Feng Duan, Na Na Dong, Ti Zhang, Qiang Li

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

To determine whether the inferior outcome noted with triple-negative breast cancer (TNBC) reflects a higher risk population among patients with breast cancer liver metastases.

Methods

A total of 123 patients with breast cancer liver metastases diagnosed at Tianjin Medical University Cancer Hospital were included in this study. Breast cancer subtype was assigned using immunohistochemistry or fluorescence in situ hybridization: hormone receptor (HR) positive (+)/human epidermal growth factor receptor 2 (HER2) negative (−), HR+/HER2+, HR−/HER2+ and triple-negative subtype. Clinical features and survival were evaluated in different subtypes.

Results

The median age at breast cancer diagnosis was 47 years (range, 23–67 years). Breast cancer subtype was confirmed in all patients (39.8% with HR+/HER2−, 24.4% with HR+/HER2+, 15.3% with HR−/HER2+ and 20.3% with TNBC). The median overall survival after liver metastases was 29 months (range, 4–89 months), and the overall 1-, 2- and 3-year survival rate was 68.3, 48.0 and 34.1%, respectively. Survival was found to be impacted by breast cancer subtype (P = 0.001), and was shortest for patients with TNBC. Time to liver metastases (TTLM) less than 24 months and liver metastasis lesions ≥3 were found to be important predictors of poor survival after liver metastases (P = 0.009 and 0.001, respectively).

Conclusions

The results indicate that clinical breast cancer subtype remains an independent prognostic predictor among patients with breast cancer liver metastases. Liver metastases arising from TNBC confers the worst prognosis, and novel agents capable of controlling intrahepatic and extrahepatic TNBC are needed.

Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300PubMedCrossRef

Hao XS, Chen KS, Liu H (2002) Analysis of female breast cancer descriptive epidemiology in Tianjin, China. Asian Pac J Cancer Prev 3:143–148PubMed

Svetlovska D, Mardiak J (2005) Treatment strategy of early-stage breast cancer. Bratisl Lek Listy 106:362–365PubMed

Hess KR, Varadhachary GR, Taylor SH et al (2006) Metastatic patterns in adenocarcinoma. Cancer 106:1624–1633PubMedCrossRef

Adam R, Aloia T, Krissat J et al (2006) Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg 244:897–907 (discussion 8)PubMedCrossRef

Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752PubMedCrossRef

Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874PubMedCrossRef

Sorlie T, Tibshirani R, Parker J et al (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 100:8418–8423PubMedCrossRef

Smid M, Wang Y, Zhang Y et al (2008) Subtypes of breast cancer show preferential site of relapse. Cancer Res 68:3108–3114PubMedCrossRef

10.

Lin NU, Claus E, Sohl J et al (2008) Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases. Cancer 113:2638–2645PubMedCrossRef

11.

Rodriguez-Pinilla SM, Sarrio D, Honrado E et al (2006) Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 12:1533–1539PubMedCrossRef

12.

Gao D, Du J, Cong L et al (2009) Risk factors for initial lung metastasis from breast invasive ductal carcinoma in stages I–III of operable patients. Jpn J Clin Oncol 39:97–104PubMedCrossRef

13.

Heitz F, Harter P, Lueck HJ et al (2009) Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer 45:2792–2798PubMedCrossRef

14.

Niwinska A, Murawska M, Pogoda K (2010) Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT). Ann Oncol 21:942–948PubMedCrossRef

15.

Nam BH, Kim SY, Han HS et al (2008) Breast cancer subtypes and survival in patients with brain metastases. Breast Cancer Res 10:R20PubMedCrossRef

16.

Anders CK, Deal AM, Miller CR et al (2011) The prognostic contribution of clinical breast cancer subtype, age, and race among patients with breast cancer brain metastases. Cancer 117:1602–1611PubMedCrossRef

17.

Harvey JM, Clark GM, Osborne CK et al (1999) Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17:1474–1481PubMed

18.

Ruers T, Bleichrodt RP (2002) Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 38:1023–1033PubMedCrossRef

19.

Nicolini A, Giardino R, Carpi A et al (2006) Metastatic breast cancer: an updating. Biomed Pharmacother 60:548–556PubMedCrossRef

20.

Liu MT, Huang WT, Wang AY et al (2010) Prediction of outcome of patients with metastatic breast cancer: evaluation with prognostic factors and Nottingham prognostic index. Support Care Cancer 18:1553–1564PubMedCrossRef

21.

Goldhirsch A, Gelber RD, Castiglione M (1988) Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women: patterns and prognoses. J Clin Oncol 6:89–97PubMed

22.

O’Reilly SM, Richards MA, Rubens RD (1990) Liver metastases from breast cancer: the relationship between clinical, biochemical and pathological features and survival. Eur J Cancer 26:574–577PubMedCrossRef

23.

Wyld L, Gutteridge E, Pinder SE et al (2003) Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer 89:284–290PubMedCrossRef

24.

Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835PubMedCrossRef

25.

Haffty BG, Yang Q, Reiss M et al (2006) Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 24:5652–5657PubMedCrossRef

26.

Chia SK, Speers CH, D’Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110:973–979PubMedCrossRef

27.

Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492–2502PubMedCrossRef

28.

Minn AJ, Gupta GP, Siegel PM et al (2005) Genes that mediate breast cancer metastasis to lung. Nature 436:518–524PubMedCrossRef

29.

Wang B, Guan ZZ, Liu DG et al (2004) Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer. Ai Zheng 23:1710–1713PubMed

30.

Lower EE, Glass E, Blau R et al (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113:301–306PubMedCrossRef

Titel: The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer
verfasst von: Xiao Feng Duan
Na Na Dong
Ti Zhang
Qiang Li
Publikationsdatum: 01.02.2013
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 1/2013
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-011-0336-x

Springer Medizin

The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer

Abstract

Background

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2013

Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients

Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastoma xenografts

Cervical stromal involvement can predict survival in advanced endometrial carcinoma: a review of 67 patients

Could salvage surgery after chemotherapy have clinical impact on cancer survival of patients with metastatic urothelial carcinoma?

Neoadjuvant and adjuvant chemotherapy with modified mesna, adriamycin, ifosfamide, and dacarbazine (MAID) regimen for adult high-grade non-small round cell soft tissue sarcomas

Paclitaxel-induced peripheral neuropathy in patients receiving adjuvant chemotherapy for breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie